Our investigational drug product candidate, DM199 is a synthetic form of the human tissue kallikrein-1 protein (KLK1), which is primarily produced in the kidneys, as well as in the pancreas and salivary glands. We believe that DM199 has the potential to treat several diseases where sufficient levels of KLK1 are necessary for healthy function.
ReMEDy2 is a Phase 2/3 study investigating DM199 (rhKLK1) as a novel acute ischemic stroke (AIS) treatment intended to safely improve stroke recoveries in a patient population with no treatment options.
In a patient population with no treatment options.
VISIT ON CLINICALTRIALS.GOVFor more information on enrollment in our current clinical trials, please contact us or visit clinicaltrials.gov for location information.
The safety and efficacy of the investigational use of this product have not been determined. There is no guarantee that the investigational use listed will be filed with and/or approved for marketing by a regulatory agency.
